In the non-CMM group, patients with OSA were predominantly male, had higher rates of hypertension and prior percutaneous coronary intervention (PCI), and were more likely to use ticagrelor and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) (p < 0.05) (Table 1). The gene discussed is ACE; the disease is hypertensive disorder.